Clinical data | |
---|---|
Other names | ISIS-426115; ISIS-GCCRRx |
Drug class | Antiglucocorticoid |
Identifiers | |
UNII |
IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2. [1] [2] It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported. [1] The drug is an antisense oligonucleotide against the glucocorticoid receptor. [1] As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2. [1]